Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients

Wei Sheng Chen, Chun Yu Liu, Hui Ting Lee, Kelvin Tsai, Yi Chun Lin, Der Cherng Tarng, Chao Hung Ho, Hsiao Yi Lin

研究成果: 雜誌貢獻文章同行評審

14 引文 斯高帕斯(Scopus)


Anemia in rheumatoid arthritis (RA) is multifactorial. Iron deficiency, either definite or relative (defect in iron utilization), exists in RA patients with anemia. Intravenous iron therapy is indicated in severe and symptomatic cases or those with conditions precluding use of oral iron, but its safety and long-term efficacy have not been well-established. Forty severe anemic (hemoglobin < 9 g/dL) RA patients with or without demonstrable bone marrow iron stain were enrolled in this study. Fractionated administration of intravenous iron saccharate was undertaken and the median follow-up time was 1 year. All patients exhibited significant elevations of hemoglobin 3 months after treatment, which were more pronounced in the nonstainable iron marrow subjects {median (interquartile range): 3.8 (2.9-4.8) g/dL versus 2.9 (2.0-3.0) g/dL, p < 0.01}. Thereafter, hemoglobin remained at a plateau level that lasted during the observation period. Throughout the whole course, none of the cases exhibited side effects or flare up of disease activities. The use of intravenous iron saccharate, preferably administrated in a fractionated way, is effective in the correction of severe anemia in RA patients, especially those with nonstainable iron marrow.
頁(從 - 到)469-477
期刊Clinical Rheumatology
出版狀態已發佈 - 3月 1 2012

ASJC Scopus subject areas

  • 風濕病


深入研究「Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients」主題。共同形成了獨特的指紋。